RLMD
RELMADA THERAPEUTICS, INC. · Healthcare · Market cap $342.4M
Insiders bought $1.7M net in the last 90 days ·0 sellers, 2 buyers· latest Form 4 filed Sep 11, 2026
Insider Buying
$4.0M
reported purchases (SEC code P)
Insider Selling
$0
reported sales (SEC code S)
Unique Insiders
4
in the rolling window
Latest filing
Sep 11, 2026
Shenouda Maged
RELMADA THERAPEUTICS, INC. (RLMD) has 8 SEC Form 4 filings (10 transaction rows) in the rolling window, disclosed by 4 distinct insiders. Most recent filing: Sep 11, 2026.
Inside the rolling window, 4 insiders at RELMADA THERAPEUTICS, INC. reported 10 open-market purchases totaling $4.0M and no open-market sales. The most active filer is Chief Financial Officer Shenouda Maged with 4 filings. Insiders have net bought $1.7M over the trailing 6 months. The most recent open-market filing is a purchase of 120,200 shares by Chief Financial Officer Shenouda Maged, dated Sep 9, 2026, worth $505K.
- Industry:Biotechnology
- CEO:Sergio Traversa
- Employees:17
- HQ:Coral Gables, FL, US
- IPO:2014-06-20
| Source | |||||||
|---|---|---|---|---|---|---|---|
Shenouda MagedFirst in 9 months | Chief Financial Officer | Purchase | 120,200 | $505K | Sep 11 | -29.0% | SEC ↗ |
Shenouda MagedFirst in 9 months | Chief Financial Officer | Purchase | 79,800 | $339K | Sep 11 | -29.0% | SEC ↗ |
TRAVERSA SERGIOFirst in 9 months | Chief Executive Officer | Purchase | 100,000 | $418K | Sep 11 | -29.0% | SEC ↗ |
TRAVERSA SERGIOFirst in 9 months | Chief Executive Officer | Purchase | 100,000 | $410K | Sep 11 | -29.0% | SEC ↗ |
| Chief Financial Officer | Purchase | 11,665 | $48K | Dec 16 | -28.7% | SEC ↗ | |
| Chief Executive Officer | Purchase | 27,500 | $113K | Dec 16 | -28.7% | SEC ↗ | |
Shenouda MagedFirst filing | Chief Financial Officer | Purchase | 500,000 | $1.1M | Nov 6 | +23.0% | SEC ↗ |
TRAVERSA SERGIOFirst filing | Chief Executive Officer | Purchase | 272,500 | $600K | Nov 6 | +23.0% | SEC ↗ |
Kelly Paul EdwardFirst filing | Chief Operating Officer | Purchase | 90,000 | $198K | Nov 6 | +23.0% | SEC ↗ |
Ence ChuckFirst filing | CAO and COO | Purchase | 136,000 | $299K | Nov 6 | +23.0% | SEC ↗ |
Earnings: last 7 quarters
Congress trading RLMD 2 all-time
- RRep. Chris JacobsOther$1,001 - $15,0002022-12-12
- RRep. Chris JacobsPurchase$1,001 - $15,0002022-11-08
STOCK Act disclosures are filed up to 45 days after the trade. Amount is a disclosed range, not an exact figure.
Frequently asked questions
How many SEC Form 4 insider filings does RLMD have?
RELMADA THERAPEUTICS, INC. (RLMD) has 8 SEC Form 4 filings (10 transaction rows) in the rolling 365-day window, disclosed by 4 distinct insiders. Most recent filing: Sep 11, 2026.
When was the most recent SEC Form 4 filing for RLMD?
The most recent Form 4 filing for RLMD on Tracefour is dated Sep 11, 2026.
Who is the most active insider at RLMD?
The most active SEC Form 4 filer at RLMD in the rolling window is Chief Financial Officer Shenouda Maged, with 4 filings.
What is the net insider flow at RLMD over the last 6 months?
Over the trailing 180 days, insiders at RLMD have net bought $1.7M based on SEC Form 4 disclosures.
What is the total insider buy and sell value at RLMD in the current window?
Inside the rolling window, insiders at RLMD bought $4.0M and sold $0 based on SEC Form 4 filings.
Can I get alerts for RLMD insider trading?
Yes. Tracefour sends a free email when a new SEC Form 4 purchase or sale is filed at RELMADA THERAPEUTICS, INC. (RLMD). Alerts are set per company from the page itself, there is no paid tier, and each email links to the original filing on SEC EDGAR.
Related companies
RELMADA THERAPEUTICS, INC. is in the Healthcare sector.